Manuel Monreal: DOACs Show Advantages Over VKAs in DVT Patients
Manuel Monreal, Coordinator of the RIETE Registry, shared a post on X about a recent article he and his colleagues co-authored, published in The European Journal of Internal Medicine, adding:
“Among DVT patients with similar eligibility for the pivotal RCTs, DOACs were associated with lower risks of recurrent VTE and major bleeding.
But no significant reduction was observed in trial-ineligible patients (around 15 percent of the total).”
Title: Recurrent venous thromboembolism and bleeding during anticoagulation in patients with deep-vein thrombosis treated with vitamin K antagonists or direct oral anticoagulants: insights from the RIETE registry
Authors: Paolo Prandoni, Raffaele Pesavento, Franca Bilora, Benjamin Brenner, Iria Francisco, Germán Sierra-Palomares, Ángeles Fidalgo, Jana Hirmerova, Samuel Fonseca, Manuel Monreal
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 8, 2026, 14:43Kemal Karaagac: LAAC vs DOACs in Atrial Fibrillation
-
Sep 8, 2026, 14:43Talat Kılıç: Can Heparin Be Used Again After HIT?
-
Sep 8, 2026, 14:39Abdul Mannan: The Case Report That Changed How I Read Bleeding Disorders
-
Sep 8, 2026, 14:25Zain Khalpey: Why the Underlying Mechanism Matters in Myocardial Ischemia
-
Sep 8, 2026, 13:26Akhil Santhosh: Closing the Gap in Chemotherapy-Induced Thrombocytopenia
-
Sep 8, 2026, 13:12Roman Rodionov: Is Lp(a) Another Homocysteine?
-
Sep 8, 2026, 12:48Denis Oduor: Beyond the Donation Chair and Into a Legacy of Hope
-
Sep 8, 2026, 12:24Alejandro González Veliz: Can a Stent Cause a Heart Attack?
-
Sep 8, 2026, 11:15Andreas Tridimas: Atherosclerosis Is Greyer Than We Admit